Nargenicin A1 isolated from Actinomyces sp. Gö301 is a 28-membered polyketide macrolide, with antibacterial activity against methicillin-resistant Staphylococcus aureus.

Nargenicin A1 is an antibiotic against Gram-positive bacteria, particularly Staphylococcus and Clostridia. It is more effective against multi-resistan strains(MRSA) than erythromycin and vancomycin. But it shows low cytotoxicity compared to erythromycin and spiramycin. Nargenicin A1 inhibits cell proliferation and induces HL-60 cell differentiation in combination with 1,25-Dihydroxyvitamin-D₃ and ATRA.

Product Rerences

• Effect of different biosynthetic precursors on the production of nargenicin A1 from metabolically engineered Nocardia sp. CS682., Koju D, et al, J Microbiol Biotechnol., 22(8):1127-32 (2012)

• Nargenicin enhances 1,25-dihydroxyvitamin D(3)- and all-trans retinoic acid-induced leukemia cell differentiation via PKCbetaI/MAPK pathways., Kim SH, et al, Biochem Pharmacol., 77(11):1694-701 (2009)

• Nargenicin attenuates lipopolysaccharide-induced inflammatory responses in BV-2 cells, Yoo JC, et al, Neuroreport, 20(11):1007-12 (2009)